Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 30 min ago
Peer-reviewedCC BY-NC-ND 4.0Clinical Medicine

Updates to contemporary care of glioblastoma

  • Bernadeth Lyn C. Piamonte1
  • Wiley Gillam2
  • Megan E.H. Still3
  • Ashley P. Ghiaseddin3
  • Matt Williams4
  • Sara Elsharkawy4,5
  • Christine Lu-Emerson6
6 affiliations
  1. 1Department of Neurology, MaineHealth Maine Medical Center, Portland, ME, USA
  2. 2College of Medicine, University of Florida, Gainesville, FL, USA
  3. 3Department of Neurosurgery, College of Medicine, University of Florida, Gainesville, FL, USA
  4. 4Imperial College Healthcare NHS Trust, London, UK
  5. 5National Cancer Institute, Cairo University, Cairo, Egypt
  6. 6Department of Neurology and Oncology, MaineHealth Maine Medical Center, Scarborough, ME, USA
Read full textPDFDOICite

Abstract

Glioblastoma is the most common and aggressive primary malignant brain tumour in adults. Over the years, the diagnostic criteria have been refined, incorporating molecular markers with histology to reflect the underlying tumour biology. Advances in genomics and molecular techniques are currently focused on trying to subcategorise the tumours for potential prognostic and clinical purposes. Treatment consists of multiple modalities including surgery, radiation, and systemic treatments. While targeted therapy traditionally has not been effective due to the heterogeneity of the tumour, fusions and certain mutations may benefit from specific targeted therapies. Tumour treating fields is a novel treatment that has shown survival benefit in newly diagnosed glioblastoma, and ongoing trials are underway to capitalise on its mechanism. Finally, special consideration should be given to palliative care in light of the high morbidity and mortality associated with glioblastoma. In particular, the balance of aggressive care and quality of life must be weighed in the geriatric population though contemporary studies have shown good tolerance for a hypofractionated course of chemoradiation.

Related

  1. Adult IDH-wildtype glioblastoma in Mexico and Latin America: contemporary standards, emerging strategies, and an evidence-to-implementation roadmap
    Alejandro Rodríguez Camacho, Emmanuel Polito-Salazar, Ximena Blasco +25
    Frontiers in OncologyPeer-reviewedCC BY 4.0Full textHuman geneticsCrossrefDOAJ
  2. Low-Dose Radiation Therapy for Osteoarthritis: A Critical Review and Proposal for Integration Into Contemporary Care
    Kishan M Patel, Trevor Wilson, Jessica Schuster +2
    CureusPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  3. Who is not benefitting from contemporary antiretroviral therapy? Correlates of virological non suppression among people with HIV accessing care in a Boston community health center
    Abigail W. Batchelder, Jacklyn Foley, Surabhi Iyer +2
    BMC Public HealthPeer-reviewedCC BY-NC-ND 4.0Infectious diseaseCrossref
  4. Utility of Chemotherapy for Metastatic Melanoma in the Contemporary Era and Experience with Modified Vinblastine–Cisplatin–Temozolomide at a Tertiary Care Center
    Woo Kyung Lee Doolittle, Rohit Rao, Malena Johnson +4
    BiomedicinesPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  5. From Mitral Valve Surgeon to Mitral Valve Specialist: Redefining Expertise in Contemporary Mitral Care
    Salvatore Poddi, Alessio Rungatscher
    Journal of Clinical MedicinePeer-reviewedCC BY 4.0Cardiovascular medicineCrossref

Cite

BibTeXRIS
BibTeX
@article{piamonte2026updates,
  title = {{Updates to contemporary care of glioblastoma}},
  author = {Bernadeth Lyn C. Piamonte and Wiley Gillam and Megan E.H. Still and Ashley P. Ghiaseddin and Matt Williams and Sara Elsharkawy and Christine Lu-Emerson},
  journal = {Clinical Medicine},
  year = {2026},
  month = sep,
  doi = {10.1016/j.clinme.2026.100643},
  url = {https://doi.org/10.1016/j.clinme.2026.100643},
  note = {CC BY-NC-ND 4.0},
}
RIS
TY  - JOUR
TI  - Updates to contemporary care of glioblastoma
AU  - Bernadeth Lyn C. Piamonte
AU  - Wiley Gillam
AU  - Megan E.H. Still
AU  - Ashley P. Ghiaseddin
AU  - Matt Williams
AU  - Sara Elsharkawy
AU  - Christine Lu-Emerson
PY  - 2026
DA  - 2026/09/20
JO  - Clinical Medicine
DO  - 10.1016/j.clinme.2026.100643
UR  - https://doi.org/10.1016/j.clinme.2026.100643
AB  - Glioblastoma is the most common and aggressive primary malignant brain tumour in adults. Over the years, the diagnostic criteria have been refined, incorporating molecular markers with histology to reflect the underlying tumour biology. Advances in genomics and molecular techniques are currently focused on trying to subcategorise the tumours for potential prognostic and clinical purposes. Treatment consists of multiple modalities including surgery, radiation, and systemic treatments. While targeted therapy traditionally has not been effective due to the heterogeneity of the tumour, fusions and certain mutations may benefit from specific targeted therapies. Tumour treating fields is a novel treatment that has shown survival benefit in newly diagnosed glioblastoma, and ongoing trials are underway to capitalise on its mechanism. Finally, special consideration should be given to palliative care in light of the high morbidity and mortality associated with glioblastoma. In particular, the balance of aggressive care and quality of life must be weighed in the geriatric population though contemporary studies have shown good tolerance for a hypofractionated course of chemoradiation.
SN  - 1470-2118
SN  - 1473-4893
ER  -